Objective Capital Management’s AbbVie ABBV Stock Holding History

Objective Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$292K	Sell	1,162 -82	-7%	-$17.6K	0.26%	77
2026 Q1	$271K	Buy	+1,244	New	+$276K	0.27%	75
2025 Q1	–	Sell	-1,604	Closed	-$285K	–	78
2024 Q4	$285K	Sell	1,604 -287	-15%	-$52.8K	0.19%	106
2024 Q3	$373K	Buy	+1,891	New	+$353K	0.22%	96
2024 Q1	$393K	Buy	2,159 +74	+4%	+$12.8K	0.27%	82
2023 Q4	$323K	Sell	2,085 -135	-6%	-$19.7K	0.25%	87
2023 Q3	$331K	Sell	2,220 -122	-5%	-$17.9K	0.29%	69
2023 Q2	$316K	Buy	2,342 +130	+6%	+$19.1K	0.28%	70
2023 Q1	$353K	Sell	2,212 -66	-3%	-$10.1K	0.32%	65
2022 Q4	$368K	Buy	2,278 +86	+4%	+$13.2K	0.37%	63
2022 Q3	$294K	Buy	2,192 +28	+1%	+$4.02K	0.31%	69
2022 Q2	$331K	Sell	2,164 -5	-0.2%	-$764	0.33%	70
2022 Q1	$352K	Buy	2,169 +1	+0%	+$145	0.27%	80
2021 Q4	$294K	Buy	+2,168	New	+$256K	0.21%	89

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Objective Capital Management's ABBV Position: Q2 2026 in Review

Objective Capital Management reduced its AbbVie (ABBV) stake by 6.6% in Q2 2026, selling an estimated $17.6K and leaving 1,162 shares worth $292K. The position accounts for 0.26% of the portfolio, ranked #77.

Objective Capital Management first reported a position in ABBV in Q4 2021 and has held it in 14 quarters since. The position peaked at $393K in Q1 2024. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Objective Capital Management held 1,162 shares of AbbVie worth $292K as of Q2 2026.
Objective Capital Management sold 82 AbbVie shares in Q2 2026, an estimated $17.6K.
AbbVie made up 0.26% of Objective Capital Management's portfolio in Q2 2026, its #77 holding.
Objective Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 14 quarters since.
Objective Capital Management's AbbVie position peaked at $393K in Q1 2024.
4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Objective Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.